Following the FDA’s safety warnings, a shift is seen away from JAK inhibitors for the treatment of rheumatoid arthritis. The changes in the market, and the need for new treatment options, highlight the possibilities for RA drugs under development with new mechanisms of action.
On the Nordic biotech map, there are some companies that specifically focus on this. One of them is Umeå-based Lipum, which is in a late preclinical phase with the biological drug candidate SOL-116, an antibody that blocks Bile-Salt Stimulated Lipase which is a previously overlooked target molecule of the immune system.
Read the article.